Novo Nordisk's pricing techniques inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of value gouging, declaring the stark contrast in between U.S. selling prices and people in Europe and copyright. are scheduled to acquire surgical